Full-Time

Director Information Security

GCC India & JAPAC

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals

10,001+ employees

Develops biopharmaceutical therapies for serious diseases

No salary listed

Hyderabad, Telangana, India

Hybrid

Hybrid role in Hyderabad.

Bachelor's

Category
IT & Security (1)
Required Skills
LLM
Incident Response
Vulnerability Analysis
SOC 2
SCRUM
HIPAA

Get referred to Regeneron Pharmaceuticals

See people who can refer or advise you

Requirements
  • A bachelor's degree in Computer Science, Information Technology, Cybersecurity, Engineering, or a related discipline is required.
  • Significant leadership experience managing enterprise Information Security organizations within global companies is required.
  • Deep expertise across cyber operations, incident response, cyber risk and assurance, data protection, AI security, security architecture, identity and access management, vulnerability management, and attack surface management is required.
  • Demonstrated success leading security engineering, operations, architecture, and delivery teams in complex global environments is required.
  • Experience with modern security technologies including SIEM/SOAR, EDR/XDR, cloud security, IAM/PAM, DLP, and vulnerability management platforms is required.
  • Strong knowledge of security frameworks and regulations including NIST CSF, ISO 27001, SOC 2, GDPR, HIPAA, SOX IT controls, and GxP data integrity requirements is required.
  • Experience evaluating, implementing, and governing AI and GenAI security capabilities within regulated environments is required.
  • A proven track record of building, scaling, and retaining high-performing technical organizations is required.
  • Experience establishing or significantly expanding Global Capability Center operations, including workforce transformation and organizational growth initiatives, is required.
  • Strong strategic planning, business insight, and decision-making skills are required, with the ability to translate ambiguity into actionable security strategies.
  • Exceptional written, verbal, and executive communication skills are required, with experience engaging senior collaborators across multiple geographies and cultures.
  • Familiarity with APAC information security and privacy regulations, including India's Digital Personal Data Protection Act and related regional requirements, is required.
  • Experience within pharmaceutical, biotechnology, life sciences, or other highly regulated industries is required.
  • Experience operating security programs across multiple jurisdictions and compliance frameworks simultaneously is required.
Responsibilities
  • Build, lead, and scale the India GCC Information Security organization, fostering a high-performance, inclusive culture focused on accountability, innovation, and continuous improvement.
  • Provide leadership across Cyber Operations, Cyber Risk & Assurance, Data Protection & AI Security, Security Architecture, Identity & Access Management, and Attack Surface Management.
  • Lead end-to-end delivery across security engineering, operations, architecture, and data teams using agile and traditional delivery models.
  • Drive adoption and optimization of SIEM/SOAR, EDR/XDR, cloud-native security platforms, IAM/PAM, DLP, and vulnerability management solutions.
  • Establish the India GCC security organization as a strategic extension of the global security team, ensuring operational excellence, delivery predictability, and continuous process improvement.
  • Lead recruiting, onboarding, workforce planning, contractor-to-FTE conversions, and capability expansion across security functions.
  • Serve as the JAPAC Information Security lead, representing Regeneron's security posture to business, regulatory, and partner collaborators throughout the Asia-Pacific region.
  • Design and oversee security governance, risk management, compliance, and control assurance programs aligned with industry frameworks and regulatory requirements.
  • Ensure continuous audit, inspection, and compliance readiness across security programs and technology environments.
  • Partner with executive leaders to translate business objectives into security strategies, investment priorities, and organizational initiatives.
  • Communicate complex security, technology, regulatory, and risk matters to executive, board-level, and operational audiences with clarity and credibility.
  • Evaluate and govern AI and GenAI capabilities to enhance security operations while maintaining compliance, privacy, and governance standards.
Desired Qualifications
  • Relevant certifications such as CISSP, CISM, CISA, CCSP, PMP, SAFe, Scrum, or cloud security certifications.
Regeneron Pharmaceuticals

Regeneron Pharmaceuticals

View

Regeneron Pharmaceuticals develops and commercializes medicines for serious diseases, with a focus on cancer, eye diseases, allergic and inflammatory diseases, and infectious diseases. Its products come from using proprietary research capabilities and technologies to discover and develop therapies, often in collaboration with academic, research, and industry partners. Revenue comes from selling approved medicines and from licensing its technologies and entering co-development and co-commercialization partnerships. The company works with healthcare providers and regulators to ensure treatment delivery and safety. Its goal is to improve patient outcomes by bringing life-transforming medicines to market through rigorous R&D and strategic collaborations, maintaining leadership in biopharmaceutical innovation.

Company Size

10,001+

Company Stage

IPO

Headquarters

Town of Mount Pleasant, New York

Founded

1988

Get referred to Regeneron Pharmaceuticals

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Pasatru won FDA approval on August 19, 2026 for ultra-rare FOP.
  • Q2 2026 revenue rose 17% to $4.3 billion, beating expectations decisively.
  • Cemdisiran received FDA and EMA review acceptance in June 2026 for gMG.

What critics are saying

  • Fianlimab failed its May 15, 2026 melanoma endpoint, triggering securities litigation.
  • Sandoz and Biocon biosimilars launch Eylea copies in late 2026, crushing margins.
  • Dupixent faces patent expiry around 2031, and Infinimmune is already building IL-13 rivals.

What makes Regeneron Pharmaceuticals unique

  • Dupixent and Eylea HD still dominate, with Q2 2026 sales hitting new highs.
  • Regeneron's VelocImmune platform keeps producing first-in-class antibodies like Libtayo and Pasatru.
  • The Sanofi collaboration generated $2.2 billion in Q2 2026 revenue, funding relentless R&D.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Wellness Program

Paid Vacation

Equity Awards

Annual Bonuses

Flexible Work Hours

Growth & Insights and Company News

Headcount

6 month growth

10%

1 year growth

10%

2 year growth

10%
PR Newswire
Aug 21st, 2026
Regeneron Pharmaceuticals, Inc. sued for securities Law violations - contact the DJS Law Group to discuss your rights - REGN.

Regeneron Pharmaceuticals, Inc. sued for securities Law violations - contact the DJS Law Group to discuss your rights - REGN. Aug 21, 2026, 04:39 ET LOS ANGELES, Aug. 21, 2026 /PRNewswire/ - The DJS Law Group reminds investors of a class action lawsuit against Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ: REGN) violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of REGN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery. CLASS PERIOD: August 1, 2025 to May 15, 2026 DEADLINE: September 14, 2026 CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. The Company gave investors the impression its Phase III Fianlimab-Libtayo Study showed signs of success and minimized risks presented by the study. The Company's study ultimately failed to achieve its primary endpoint in a statistically significant manner. Based on these facts, Regeneron's public statements were false and materially misleading throughout the class period. WHY DJS LAW GROUP? DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results. David J. Schwartz DJS Law Group 274 White Plains Road, Suite 1 Eastchester, NY 10709 Phone: 914-206-9742 SOURCE DJS Law Group LLP

Associated Press
Aug 19th, 2026
FDA approves Pasatru, first treatment reducing bone lesions by 90% in adults with ultra-rare FOP

The US Food and Drug Administration has approved Regeneron's Pasatru (garetosmab-grts) to reduce new heterotopic ossification lesions and flare-ups in adults with fibrodysplasia ossificans progressiva (FOP). FOP is an ultra-rare genetic disorder affecting approximately 900 people worldwide, where rogue bone formation infiltrates muscles, tendons and connective tissues, leading to severe disability. The approval follows results from the Phase 3 OPTIMA trial involving 63 participants. At 56 weeks, Pasatru demonstrated a 90% or greater reduction in new HO lesions compared to placebo, assessed by CT scan. The 10 mg/kg dose showed an 88% reduction in clinician-assessed flare-ups. Pasatru is a fully human monoclonal antibody that blocks Activin A, a protein critical in developing HO lesions. Regeneron's regulatory submission is under review by the European Medicines Agency.

Investors Hangout
Aug 19th, 2026
Regeneron faces class action over misleading investors.

Regeneron faces class action over misleading investors. Regeneron lands in hot water over clinical trial. Here's a story that could ruffle some feathers over at Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN). Some investors are feeling burned and it's not without reason. A lawsuit has kicked off, taking aim at how the company allegedly spun a yarn over its Phase 3 trial involving Fianlimab-Libtayo. The allegations piling up. From the sound of it, Regeneron assured investors that they were onto something big with their new treatment for advanced melanoma. They were pairing Fianlimab with Libtayo in a Phase 3 setup, but it's alleged that there were some fundamental missteps they forgot to mention. Investors Hangout, LLC is talking flawed statistical assumptions and a lack of surprises from the treatment arm. Investors were, apparently, not told that the odds of the trial hitting its primary mark were slim to none. Investors accuse the biotech giant of artificially inflating its stock by not being entirely forthright. That lack of transparency has now got them in legal deep waters. Stock takes a hit. When the cat got out of the bag, it was a steep downhill for Regeneron's shares. On April 29, 2026, during their earnings call, Regeneron admitted to making changes in the trial design mid-stream. Investors didn't take this well, and the fallout was a 6.2% drop in their stock from $731.77 to $686.36 in just a day. A bombshell indeed, but it wasn't the end of the unraveling. Fast forward to May 15, 2026, and the other shoe drops. Regeneron let it be known that their trial failed to live up to its primary endpoint for progression-free survival. Ka-boom, that hit sent their shares spiraling down from $698.25 to $629.68 by May 18 - a near 10% nosedive. Who's raising their hand? The lawsuit ropes in anyone who bought into Regeneron between August 1, 2025, and May 15, 2026. If you've lost dough, mark September 14, 2026, on your calendar - that's your date to get in as a lead plaintiff if you want your voice to count in this class action suit. Digging Deeper: Lead plaintiffs don't carry the burden of costs - thanks to the magic of contingency fees. If you're considering stepping up, you won't be reaching for your wallet. It's the defendants who'll foot the bill if the case sees recovery. A look at class actions and shareholder rights. Why does this matter to the wider investor audience? Well, regulatory actions such as these keep the execs on their toes. They should know they can't treat transparency like an option; it's a must. * Shareholders rely on transparency and accurate representation. * These lawsuits remind companies about their duties to investors. * A win can restore some financial justice, albeit sometimes pennies on the dollar. Folks who've been in this game for a while know you can't hedge your bets if your information is skewed or withheld. Caution and scrutiny ahead. Looking ahead, investors in the biotech sphere, and especially in stocks like REGN, need to keep vigilant. The trial and ensuing litigation are a stark reminder that even seasoned companies can find themselves cornered. A class action like this holds echoes beyond its immediate financial implications. It's an eye-opener for anyone watching the pharmaceutical industry's dance with transparency and innovation. Keep tabs on how this shakes out because it'll likely set precedents either way - whether as a warning or a lesson in due diligence.

Pharmaceutical Technology
Aug 12th, 2026
Infinimmune raises $75m with big pharma backing for atopic dermatitis drugs.

Infinimmune raises $75m with big pharma backing for atopic dermatitis drugs. Infinimmune is targeting first-in-human studies with its longer-lasting monoclonal antibodies in 2027. Infinimmune has raised $75m in Series A financing, helping the biotech advance its atopic dermatitis (AD)-centric pipeline. As part of the round, Infinimmune garnered the interest of several major industry players, including Regeneron's venture, which co-led the biotech's raise with Playground Global, while MSD's (Merck & Co) global health innovation fund participated alongside other life sciences investors. Infinimmune already has a clear area in which it will spend the Series A tranche. While not disclosing how it will split the money, the biotech said the financing will accelerate clinical development of its two lead programmes in AD, as well as supporting additional programmes and advancing its Anthrobody discovery platform. Infinimmune's platform helps create longer-lasting antibodies while maintaining potency. It does this by screening millions of single memory B cells across hundreds of targets to identify natively paired, fully human antibodies. So far, the company has IFX-101 and IFX-201, monoclonal antibodies that target IL-22 and IL-13, respectively. First-in-human studies with the assets are slated to begin in 2027. Wyatt McDonnell, co-founder and CEO of Infinimmune, said: "The human immune system makes extraordinary antibodies. We built a company to find them and are uniquely positioned to turn them into transformative medicines for patients with unmet needs. This financing enables Infinimmune to bring that promise to the clinic, as we work alongside a world-class syndicate to develop the molecules that patients living with inflammatory diseases deserve." For Regeneron, contributing to Infinimmune's development means it is advancing a potential rival to Dupixent (dupilumab), the blockbuster anti-inflammatory injection that has dominated the AD landscape for years. Dupixent, co-marketed with Sanofi, targets both IL-4 and IL-13, meaning there is some overlap with Infinimmune's pathway targets. The patents for Dupixent, which generated $17.8bn in sales in 2025, are set to expire around 2031. Regeneron and Sanofi are already building out their pipelines to preserve their dominance in the AD market, though assets like those being developed by Infinimmune could provide future bolt-on options. Infinimmune is targeting a crowded yet lucrative market. GlobalData forecasts that AD across the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan) will be worth $22.4bn in 2033. GlobalData is the parent company of Pharmaceutical Technology. MSD, meanwhile, is already familiar with Infinimmune. In March 2026, Infinimmune signed a multi-target antibody discovery collaboration with the big pharma company that includes up to approximately $838m in upfront and potential milestone payments.

The Pharma Letter
Aug 8th, 2026
Biocon announces commercial launch of Yesafili in USA.

Biocon announces commercial launch of Yesafili in USA. 7 August 2026 India's Biocon (BSE: 5325) has announced the commercial launch of Yesafili (aflibercept-jbvf) in the USA. Yesafili, a vascular endothelial growth factor (VEGF) inhibitor used to treat various types of ophthalmology conditions, is a biosimilar of its reference product Eylea (aflibercept) 2-mg, originated by US biotech Regeneron (Nasdaq: REGN) and licensed to Germany's Bayer (BAYN: DE). The product was approved previously and granted interchangeable designation by the US Food and Drug Administration (FDA) in May 2024, allowing substitution at the pharmacy level in accordance with state laws. However, Biogen only reached an agreement with Regeneron to launch the biosimilar in the second half of 2026. This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here. Try before you buy Free. 7 day trial access * All the news that moves the needle in pharma and biotech * Exclusive features, podcasts, interviews, data analyses and commentary from its global network of life sciences reporters. * Receive The Pharma Letter daily news bulletin, free forever. Become a subscriber £820. Or £77 per month * Unfettered access to industry-leading news, commentary and analysis in pharma and biotech. * Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results. * Daily roundup of key events in pharma and biotech. * Monthly in-depth briefings on Boardroom appointments and M&A news. * Choose from a cost-effective annual package or a flexible monthly subscription The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It's part of the key information for keeping me informed Chairman, Sanofi Aventis UK More on this story... 21 May 2024 24 October 2024 17 April 2025 Companies featured in this story. Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news Today's issue. 7 August 2026 Company spotlight. A San Carlos, California-based immunology biotech using nanobody-based multispecific biologics to target the IL-31 itch pathway, positioning its lead asset against the Dupixent franchise in atopic dermatitis and chronic pruritus. More features in biosimilars. 5 August 2026 31 July 2026 23 July 2026 22 July 2026